Science & Technology
Development of Digital Satiorx, a Very Low Cost Remotely Controllable Disposable Microneedle Transdermal Drug Delivery Device Able to Deliver Any Liquid Fda Approved Transdermal Drug
Department of Health and Human Services — National Institutes of Health
Opportunity #: 75N91023C00059
Award Ceiling
$3.5M
Award Floor
$3.5M
Close Date
N/A
Total Funding
$3.5M
Expected Awards
1
Cost Sharing Required
No
Grants.gov ID
sbir-75N91023C00059
Description
SBIR Phase Phase II award: "DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG" awarded to SATIO INC in BOSTON, Massachusetts. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $3,500,000. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.